Remdesivir for COVID19

Safety & Antiviral Activity of Remdesivir for severe COVID-19 (Gilead 5773)

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).

Imperial PI Professor Sarah Fidler
Trial Sponsor Gilead Sciences Inc.
Study type Interventional
Study status Closed to recruitment

Find out more about this study here.
ClinicalTrials.Gov record


Safety & Antiviral Activity of Remdesivir for moderate COVID-19 (Gilead 5774)

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to the time to discharge in participants with moderate coronavirus disease (COVID-19).

Imperial PI Professor Graham Cooke
Trial Sponsor Gilead Sciences Inc.
Study type Interventional
Study status Closed to recruitment

Find out more about this study here.
ClinicalTrials.Gov record

Participants recruited to date: